AstraZeneca is strengthening its oncology portfolio with another major strategic investment, signing an exclusive global licensing agreement worth up to $1.5 billion for Zegfrovy, an innovative targeted therapy for a specific type of lung cancer developed by China’s Dizal Pharmaceutical.
The London-based biopharmaceutical company announced that it will acquire worldwide rights to develop and commercialize Zegfrovy (sunvozertinib) through an exclusive agreement with Dizal Pharmaceutical. The transaction, which is expected to close during the second half of 2026, underscores AstraZeneca’s continued focus on expanding its precision oncology pipeline.
Under the terms of the agreement, AstraZeneca will pay $600 million upfront, while Dizal will be eligible to receive up to $900 million in additional milestone payments tied to development, regulatory, and commercial achievements. The Chinese drugmaker will also earn tiered royalties based on future global sales of the medicine.
Expanding Treatment Options for Lung Cancer Patients
Zegfrovy is an oral, irreversible epidermal growth factor receptor (EGFR) inhibitor designed to treat adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations whose disease has progressed following platinum-based chemotherapy. The therapy has already secured regulatory approvals in both the United States and China, positioning it as an important treatment option for patients with limited alternatives.
Non-small cell lung cancer accounts for the majority of lung cancer diagnoses worldwide, making the addition of a targeted therapy like Zegfrovy particularly significant for precision medicine approaches. Clinical studies have demonstrated encouraging efficacy for patients with this rare genetic mutation, supporting AstraZeneca’s decision to bring the treatment into its global oncology portfolio.
Strengthening AstraZeneca’s Oncology Leadership
The licensing agreement complements AstraZeneca’s extensive portfolio of therapies targeting EGFR-driven cancers and reflects the company’s strategy of acquiring innovative medicines with strong global commercialization potential. By securing worldwide development and marketing rights, AstraZeneca aims to expand access to the therapy across additional markets while exploring future clinical opportunities.
The transaction also reinforces AstraZeneca’s growing collaboration with China’s life sciences sector, where the company has continued to invest in research partnerships and innovative drug development. Industry observers view the agreement as another example of global pharmaceutical companies increasingly looking to Chinese biotech firms for breakthrough therapies.
Financial Impact and Closing Timeline
AstraZeneca said the investment is not expected to affect its financial guidance for 2026. Completion of the licensing transaction remains subject to customary closing conditions and is anticipated during the second half of the year.
With Zegfrovy joining its expanding oncology portfolio, AstraZeneca continues to invest aggressively in targeted cancer therapies, reinforcing its ambition to deliver innovative treatments for patients facing difficult-to-treat forms of lung cancer while strengthening its long-term growth strategy in precision medicine.
Read more: Intel Invests €5 Billion in Ireland to Expand AI Chip Manufacturing Capacity
